| CAS | 108736-35-2 |
| Sequence | H-D-2-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 (Disulfide bond) |
| Sequence Single | H-D-2-Nal-CYwKVCT-NH2 |
| Molecular Formula | C54H69N11O10S2 |
| Molecular Weight | 1096.34 |
| Synonyms | BIM-23014, DC-13-116, (D-2-Nal5,Cys6.11,Tyr7,D-Trp8,Val10)-Somatostatin (5-12) amide, Somatostatin Tumor Inhibiting Analog |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Cancer Research |
| Description | Lanreotide also called BIM-23014, DC-13-116, (D-2-Nal5,Cys6.11,Tyr7,D-Trp8,Val10)-Somatostatin (5-12) amide, Somatostatin Tumor Inhibiting Analog, a cyclic somatostatin agonist shows a high binding affinity for the somatostatin receptor (SSTR) subtype 2 and has a 10-fold less affinity for receptor subtype 5. It is also a potent inhibitor of growth hormone secretion from pituitary cells. Furthermore, the octapeptide exhibits a direct antiproliferative effect in vivo and in vitro on the growth of cells or solid tumors from a human small cell lung carcinoma. CAS Number (lanreotide acetate): 127984-74-1. |
| References | 1. Maxadilan, a PAC1 receptor agonist from sand flies. E.A.Lerner et al., Peptides, 28, 1651 (2007) 2. Somatostatin acts by inhibiting the cyclic 3’,5’-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency. J.J.Tentler et al., Mol. Endocrinol., 11, 859 (1997) 3. Structure and function of somatostatin receptors in growth hormone control. I.Shimon and S.Melmed, J. Endocrinol., 155, S3 (1997) 4. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. Ning S, et al. Endocr Relat Cancer. 2009 Sep;16(3):1045-55. 5. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Florio T, et al. Clin Endocrinol (Oxf). 2003 J. |